Dustri Online Services

Books: 0	Journals: 1	Articles: 28

Abstract

Clinical Neuropathology, Vol. 34 – No. 5/2015 – Letters to the editor

Tumor-to-tumor metastasis – bronchial carcinoma in meningioma

Melanie Hamperl¹, Felix Goehre¹, Stefan Schwan¹, Behnam Rezai Jahromi¹, Andrea Friedmann¹, Christopher Michael Ludtka¹, Thomas Mendel¹, Lhagva Sanchin¹, Christian Bodo Kern¹, Hans Jörg Meisel¹, and Christian Mawrin²

¹Department of Neurosurgery, Bergmannstrost Hospital Halle, Halle, and ²Department of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
Correspondence to:
Felix Goehre, MD
Department of Neurosurgery
Bergmannstrost Hospital
Merseburger Straße 165, 06112 Halle, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 39 – No. 5/2020 (203-211)

Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019

Markus J. Riemenschneider¹, Josephine Fischer², Maja Grassow-Narlik², Christian Mawrin³, Andreas von Deimling⁴, Torsten Pietsch⁵, Guido Reifenberger⁶, Wolf C. Mueller⁷, Clemens J. Sommer⁸, Manfred Dietel², Saida Zoubaa¹, Julia Lorenz¹*, and Tanja Rothhammer-Hampl¹*

¹Department of Neuropathology, Regensburg University Hospital, Regensburg, ²Quality Assurance Initiative Pathology (QuIP) GmbH, Berlin, ³Institute of Neuropathology, Otto-von-Guericke University, Magdeburg, ⁴Department of Neuropathology, Heidelberg University Hospital, and CCU Neuropathology, DKFZ, Heidelberg, ⁵Department of Neuropathology & DGNN Brain Tumor Reference Center, University of Bonn Medical Center, German Center for Neurodegenerative Diseases of the Helmholtz Association, Bonn, ⁶Institute of Neuropathology, Medical Faculty, Heinrich Heine University, Düsseldorf, ⁷Department of Neuropathology, University Hospital Leipzig, Leipzig, and ⁸Institute of Neuropathology, University Medical Center, Johannes Gutenberg-University of Mainz, Mainz, Germany
We here report on the first neuropathological round robin trials initiated by the Quality Assurance Initiative Pathology (QuIP) in Germany in the years 2018 and 2019. Testing services as external laboratory controls were offered for IDH1-R132H immunohistochemistry in 2018 followed by a molecular trial for IDH1 and IDH2 mutations in 2019 including the rare mutational variants. Also in 2019, a trial on MGMT promoter methylation testing was offered. On a national scale, trial offers were well received with around 40 participating institutions. The international announcement of the molecular IDH1/IDH2 mutational trial achieved only moderate European outspread. Success rates in all three trials were excellent (IDH1-R132H immunohistochemistry 2018: 94%, 18 out of 20 possible points required; IDH1/IDH2 mutational status 2019: 100%, 19 out of 20 possible points required; MGMT promoter methylation 2019: 94%, 19 out of 20 possible points required) indicating that quality standards are high in the broad majority of the institutions. Trial participation also involved filling in a questionnaire asking for background information on local testing procedures. We here present a first assessment of the information collected providing unique insights in the landscape of molecular testing in neuropathology. Derived from this information we identify future challenges and provide an outlook on the development of quality assurance in the field of neuropathology.

*Both authors contributed equally to this manuscript.Correspondence to:
Markus J. Riemenschneider, MD
Department of Neuropathology
Regensburg University Hospital
Franz-Josef-Strauss-Allee 11
93053 Regensburg, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 41 – No. 4/2022 (174-178)

Life and death of molecular subclones in recurrent meningioma: A case study

Niklas Abele¹, Elmar Kirches¹, I. Erol Sandalcioglu², Werner E.K. Braunsdorf³, and Christian Mawrin¹

¹Neuropathology, ²Neurosurgery, Otto-von-Guericke University, and ³Neurosurgery, City Hospital, Magdeburg, Germany
Meningiomas are the most common primary intracranial tumors, of which atypical meningiomas account for ~ 20%. A loss of NF2 has been proven to be an initial step for meningioma development; however, the role of non-NF2 alterations is unknown. Here we report a case of an atypical meningioma with a NF2 splice donor mutation and four recurrences. Using a custom NGS panel, further complex heterogenic molecular alterations were discovered. At first, one subclone of the initial tumor showed an additional PIK3CA variant, most likely of no pathogenic relevance. Then, the first and second recurrences no longer harbored the PIK3CA variant and no tumor heterogeneity was found. The tumor-driving NF2 mutation persisted, however. The latest, third recurrence showed a remarkable genetic heterogeneity with multiple, additional non-NF2 variants and a pathogenic PIKC3A mutation. In detail, one subclone showed a SUFU and two SMARCE1 variants. Another, geographically separate tumor subclone, in contrast, showed several different non-NF2 variants in SMO, PIK3CA and SUFU. Most important, one of the newly acquired PIK3CA alterations in the kinase domain (L1006F) is likely to be an additional tumor-driving mutation, which activates the PI3K-AKT-mTOR pathway. The reported genetic heterogeneity in meningiomas has been addressed in only a few studies. Although some of the detected variants in our case are expected to have biochemical consequences, these consequences are usually not likely to promote tumor development, when taking into account the suggested role of the altered proteins in tumorigenic pathways. However, the occurrence of a single oncogenic missense mutation in a subclone of the third recurrence may indicate a clonal change towards enhanced aggressiveness. Taken together, our case supports the need to perform in-depth studies to clarify the role of non-NF2 mutations for meningioma growth and development.Correspondence to:
Prof. Christian Mawrin, MD
Department of Neuropathology
Otto-von-Guericke-University
Leipziger Strasse 44, 39120 Magdeburg, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 41 – No. 4/2022 (151-152)

Clinical Neuropathology 4-2022

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 41 – No. 5/2022 (195-196)

Clinical Neuropathology 5-2022

Christian Mawrin

Department of Neuropathology Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 41 – No. 6/2022 (243-244)

Clinical Neuropathology 6-2022

Christian Mawrin

Abstract

Clinical Neuropathology, Vol. 42 – No. 1/2023 (26-29)

Colloid cyst with hyphal-like structures: A rarity that mimics actinomycosis of athe third ventricle

Dirar Aldabek¹, Martina Deckert², Christian Mawrin³, and Jan-Peter Warnke¹

¹Department of Neurosurgery/Paracelsus-Kliniken, Zwickau, ²Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, Cologne, and ³Department of Neuropathology, Otto von Guericke University Magdeburg, Magdeburg, Germany
Colloid cysts are histologically well defined and consist of three main components, a capsule, with an underlying epithelial layer, and a mucinous heart. In our case, we present a 35-year-old female with acute deterioration of level of consciousness. An emergent CT scan showed a cystic lesion occluding the intraventricular foramen. The lesion was endoscopically excised through a transfrontal approach. Microscopic examination of the resected specimen revealed hyphal-like structures (HLS). This rare finding was first described by Dodds and Powers in 1977 and, in its microscopic nature, it mimics actinomyces of the third ventricle. Correspondence to:
Christian Mawrin, MD
Department of Neuropathology
University Hospital Magdeburg, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 42 – No. 1/2023 (1)

Clinical Neuropathology 1-2023

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 42 – No. 2/2023 (45-46)

Clinical Neuropathology 2-2023

Christian Mawrin

Correspondence to:
Christian Mawrin, Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 42 – No. 3/2023 (85-86)

Clinical Neuropathology 3-2023

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 42 – No. 4/2023 (129-130)

Clinical Neuropathology 4-2023

Christian Mawrin

Abstract

Clinical Neuropathology, Vol. 42 – No. 5/2023 (173)

Clinical Neuropathology 5 & 6, 2023

Christian Mawrin

Department of Neuropathology Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 43 – No. 1/2024 (1)

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 43 – No. 3/2024 (73)

Clinical Neuropathology 3-2024

Christian Mawrin

Abstract

Clinical Neuropathology, Vol. 43 – No. 2/2024 (41-42)

Clinical Neuropathology 2-2024

Christian Mawrin

Correspondence to:
Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 43 – No. 4/2024 (103)

Clinical Neuropathology 4-2024

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 43 – No. 5/2024 (137)

Clinical Neuropathology 5-2024 Clinical Neuropathology 6-2024

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 44 – No. 1/2025 (1)

Clinical Neuropathology 1-2025

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Abstract

Clinical Neuropathology, Vol. 44 – No. 1/2025 (9-15)

Molecular evolution of metastatic meningioma: A case report

Julian Kahr¹, Klaus-Peter Stein², Peter John¹, Torsten Walles³, Martin Roepke⁴, Belal Neyazi², I. Erol Sandalcioglu², David R. Raleigh⁵, and Christian Mawrin¹

Department of ¹Neuropathology, ²Neurosurgery, ³Thoracic Surgery, and ⁴Orthopedics, Otto-von-Guericke-University, Magdeburg, Germany, and ⁵Departments of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco, CA, USA
Distant metastases in meningioma are rare, and the molecular drivers of meningioma spread are not well understood. We describe the case of a 63-year-old woman who was diagnosed with an intracranial meningioma in 2020 which was graded as an atypical meningioma with brain invasion. Local recurrence occurred 1 year later, and in 2023 bone metastases were resected from the thoracic wall and humerus. Molecular analyses from all tumor sites by next-generation sequencing and genome-wide methylation profiling revealed several molecular alterations (loss of 1chromosome 1p, 3p, 4q, 8p, 9p, 10p, 14q, 18q, 22q) already present in the first tumor which remained surprisingly stable during progression and metastasis. However, distant metastasis was exclusively associated with gain of chromosome 1q and 17q. All samples harbored a homozygous CDKN2A deletion. This case expands the knowledge about molecular alterations associated with bone metastases of aggressive meningiomas.Correspondence to:
Prof. Christian Mawrin, MD
Department of Neuropathology
Otto-von-Guericke University Magdeburg
Leipziger Strasse 44
D-39120 Magdeburg, Germany
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 44 – No. 2/2025 (43)

Clinical Neuropathology 2-2025

Christian Mawrin

Department of Neuropathology, Magdeburg, Germany

Warenkorb Übersicht
Typ	Anz	Rabatt	MwSt	Preis
Der Warenkorb ist leer

Ihr Warenkorb

Search Results

Warenkorb Übersicht

Senden Sie uns eine E-Mail